Literature DB >> 29724901

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.

Guillaume Manson1, Charles Herbaux2, Pauline Brice3, Krimo Bouabdallah4, Aspasia Stamatoullas5, Jean-Marc Schiano6, Hervé Ghesquieres7, Laurent Dercle8, Roch Houot1,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29724901     DOI： 10.1182/blood-2018-03-841262

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Authors:  Ashraf Z Badros; Ning Ma; Aaron P Rapoport; Emily Lederer; Alexander M Lesokhin
Journal:  Blood Adv       Date:  2019-06-11

2.  Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Liudmila V Fedorova; Kirill V Lepik; Natalia B Mikhailova; Elena V Kondakova; Yuri R Zalyalov; Vadim V Baykov; Elena V Babenko; Andrey V Kozlov; Ivan S Moiseev; Boris V Afanasyev
Journal:  Ann Hematol       Date:  2021-02-02       Impact factor: 3.673

Review 3.  Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.

Authors:  Xiao-Yin Zhang; Graham P Collins
Journal:  Curr Oncol Rep       Date:  2022-06-13       Impact factor: 5.075

Review 4.  Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.

Authors:  Guillaume Manson; Amaeshi Chukwunonye Lemchukwu; Fatima-Zohra Mokrane; Egesta Lopci; Nicolas Aide; Laetitia Vercellino; Roch Houot; Laurent Dercle
Journal:  Eur Radiol       Date:  2022-03-28       Impact factor: 7.034

5.  Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.

Authors:  Ayumu Ito; Sung-Won Kim; Ken-Ichi Matsuoka; Toshiro Kawakita; Takashi Tanaka; Yoshihiro Inamoto; Tomomi Toubai; Shin-Ichiro Fujiwara; Masafumi Fukaya; Tadakazu Kondo; Junichi Sugita; Miho Nara; Yuna Katsuoka; Yosuke Imai; Hideyuki Nakazawa; Ichiro Kawashima; Rika Sakai; Arata Ishii; Makoto Onizuka; Tomonari Takemura; Seitaro Terakura; Hiroatsu Iida; Mika Nakamae; Kohei Higuchi; Shinobu Tamura; Satoshi Yoshioka; Kazuto Togitani; Noriaki Kawano; Ritsuro Suzuki; Junji Suzumiya; Koji Izutsu; Takanori Teshima; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2020-08-03       Impact factor: 2.490

Review 6.  Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.

Authors:  Sabela Bobillo; Juan Camilo Nieto; Pere Barba
Journal:  Bone Marrow Transplant       Date:  2021-03-19       Impact factor: 5.174

Review 7.  The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.

Authors:  Nicholas Meti; Khashayar Esfahani; Nathalie A Johnson
Journal:  Cancers (Basel)       Date:  2018-06-15       Impact factor: 6.639

8.  Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.

Authors:  Ieva Saulite; Desislava Ignatova; Yun-Tsan Chang; Christina Fassnacht; Florentia Dimitriou; Eleni Varypataki; Florian Anzengruber; Mirjam Nägeli; Antonio Cozzio; Reinhard Dummer; Julia Scarisbrick; Steve Pascolo; Wolfram Hoetzenecker; Malgorzata Bobrowicz; Emmanuella Guenova
Journal:  Oncoimmunology       Date:  2020-03-18       Impact factor: 8.110

Review 9.  Immune-Checkpoint Blockade Therapy in Lymphoma.

Authors:  Ayumi Kuzume; SungGi Chi; Nobuhiko Yamauchi; Yosuke Minami
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

Review 10.  Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.

Authors:  Cristina Ferrari; Nicola Maggialetti; Tamara Masi; Anna Giulia Nappi; Giulia Santo; Artor Niccoli Asabella; Giuseppe Rubini
Journal:  J Pers Med       Date:  2021-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.